

Product datasheet for TL317301V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

RBM38 Human shRNA Lentiviral Particle (Locus ID 55544)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: RBM38 Human shRNA Lentiviral Particle (Locus ID 55544)

Locus ID: 55544

Synonyms: dj800j21.2; HSRNASEB; RNPC1; SEB4B; SEB4D

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: RBM38 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001291780, NM 017495, NM 183425.1, NM 183425.2, NM 017495.1,

NM 017495.2, NM 017495.3, NM 017495.4, NM 001291780.1, BC018711, BM549757,

NM 017495.6, NM 183425.3, NM 001291780.2

UniProt ID: Q9H0Z9

Summary: RNA-binding protein that specifically bind the 3' UTR of CDKN1A transcripts, leading to

maintain the stability of CDKN1A transcripts, thereby acting as a mediator of the p53/TP53 family to regulate CDKN1A. CDKN1A is a cyclin-dependent kinase inhibitor transcriptionally regulated by the p53/TP53 family to induce cell cycle arrest. Isoform 1, but not isoform 2, has the ability to induce cell cycle arrest in G1 and maintain the stability of CDKN1A transcripts

induced by p53/TP53. Also acts as a mRNA splicing factor. Specifically regulates the

expression of FGFR2-IIIb, an epithelial cell-specific isoform of FGFR2. Plays a role in myogenic

differentiation.[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).